NASDAQ:PBM 20 November 2025

Psyence BioMed (NASDAQ: PBM) Jumps as It Secures Pharmaceutical‑Grade Ibogaine Supply for Global Clinical Trials – 20 November 2025

Psyence BioMed (NASDAQ: PBM) secured a sustainable supply of pharmaceutical-grade ibogaine through PsyLabs, receiving an initial 50 kg shipment of high-potency iboga bark for processing. PBM shares rose 21.5% to $3.39 in pre-market trading Thursday, after being named among top healthcare movers.

20 November 2025

Biotechnology·NASDAQ:PBM·Pharmaceuticals·Stock Market

Sonoco (SON) Stock Shows 59.5% Undervaluation Despite Mixed Short-Term Moves
March 20, 2026, 2:09 PM EDT. Sonoco Products (ticker: SON) trades near $51.81 after a 1.8% weekly dip and 8.7% monthly decline but boasts a 13.4% gain over the past year. A discounted cash flow (DCF) analysis reveals the stock is approximately 59.5% undervalued, with an intrinsic value estimated at $127.99. This suggests the market may not fully price in Sonoco's projected cash flow growth through 2028 and beyond. Investors eyeing packaging stocks should note these mixed signals amid ongoing concerns about input costs and demand resilience. Sonoco's robust year-to-date performance contrasts with recent volatility, spotlighting valuation disparities among industrial firms. The DCF approach, focusing on free cash flow to equity, supports a favorable long-term outlook despite near-term fluctuations.